

JAN 13 2003

Sheet 1 of 4

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06666-149001	Application No. 09/997,525
		Applicant Erlinda M. Gordon et al.	
		Filing Date November 29, 2001	Group Art Unit 1646 1632

**Information Disclosure Statement
by Applicant**
(Use several sheets if necessary)

(37 CFR §1.98(b))

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
RLG	AA	6,004,798	Dec 21, 1999	Anderson et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED

JAN 15 2003

TECH CENTER 1600/2900

Foreign Patent Documents or Published Foreign Patent Applications


Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AL							
	AM							
	AN							
	AO							
	AP							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
RLG	AR	Asher, et al., "Murine Tumor Cells Transduced with the Gene for Tumor Necrosis Factor- α ", <u>The Journal of Immunology</u> , Vol. 146, No. 9, pp. 3227-3234, May 1, 1991
	AR	Blankenstein, et al., "Tumor Suppression after Tumor Cell-targeted Tumor Necrosis Factor α Gene Transfer", <u>The Journal of Experimental Medicine</u> , Vol. 173, No. 5, pp. 1047-1052, May, 1991
RLG	AS	Borrello, et al., "A Universal Granulocyte-Macrophage Colony-Stimulating Factor-Producing Bystander Cell Line for Use in the Formulation of Autologous Tumor Cell-Based Vaccines", <u>Human Gene Therapy</u> , Vol. 10, No. 12, pp. 1983-1991, August 10, 1999

Examiner Signature RLG	Date Considered 8/8/03
-------------------------------	---------------------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
06666-149001Application No.
09/997,525**RECEIVED****Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant

Erlinda M. Gordon et al.

JAN 15 2003

Filing Date

November 29, 2001

Group Art Unit

1646/6 TECH CENTER 1600/2900

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
RCS	AT	Coze, et al., "characteristics and Immunomodulatory Properties of Human Neuroblastoma Cells after Retrovirus-Mediated Gene Transfer of the Cytokine Genes IL-2 and IFN- γ ", <u>Transgenics</u> , Vol. 1, No. 6, pp. 585-595, 1995
	AU	Dranoff, et al., "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity", <u>Proceedings of the National Academy of Sciences</u> , Vol. 90, No. 8, pp. 3539-3543, April 15, 1993
	AV	Fearon, et al., "Interleukin-2 Production by Tumor Cells Bypasses T Helper Function in the Generation of an Antitumor Response", <u>Cell</u> , Vol 60, No. 3, pp. 397-403, February 9, 1990
	AW	Fong, et al., "The Use and Development of Retroviral Vectors to Deliver Cytokine Genes for Cancer Therapy", <u>Critical Reviews in Therapeutic Drug Carrier Systems</u> , Vol. 17, No. 1, pp. 1-60, 2000
	AX	Foreman, et al., "Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication", <u>British Journal of Cancer</u> , Vol. 67, pp. 933-938, 1993
	AY	Gansbacher, et al., "Retroviral lymphokine gene transfer induced secretion of Interleukin-2 (IL-2) or Interferon-gamma (IFN- γ) by human melanoma cells", Eighty-Second annual meeting of the American Association for Cancer Research Proceedings, Houston, Texas, Vol 32, 1514 (Abstract) May 15-18, 1991
	AZ	Gilboa, "Immunotherapy of Cancer with Genetically Modified Tumor Vaccines", <u>Seminars in Oncology</u> , Vol. 23, No. 1, pp. 101-107, February, 1996
	AAA	Golumbek, "Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4", <u>Science</u> , Vol. 254, pp. 713-716, 1 November 1991
	ABB	Gordon, et al., "Inhibition of Metastatic Tumor Growth in Nude Mice by Portal Vein Infusions of Matrix-targeted Retroviral Vectors Bearing a Cytocidal Cyclin G1 Construct", <u>Cancer Research</u> , Vol. 60, No. 13, pp. 3343-3347, July 1, 2000
	ACC	Gordon, et al., "Systemic Administration of a Matrix-Targeted Retroviral Vector is Efficacious for Cancer Gene Therapy in Mice", <u>Human Gene Therapy</u> , Vol. 12, No. 2, pp. 193-204, January 20, 2001
	ADD	Guinan, et al., "Pivotal Role of the B7:CD28 Pathway in Transplantation Tolerance and Tumor Immunity", <u>Blood</u> , Vol. 84, No. 10., pp. 3261-3282, November 15, 1994
	AEE	Hall, et al., "Molecular Engineering of Matrix-Targeted Retroviral Vectors Incorporating a Surveillance Function Inherent in von Willebrand Factor", <u>Human Gene Therapy</u> , Vol 22. No. 7, pp. 983-993, May 1, 2000
	AFI	Handgretinger et al., "Interferon-Gamma Upregulates the Susceptibility of Human Neuroblastoma Cells to Interleukin-2-Activated Natural Killer Cells", <u>Natural Immunity and Cell Growth Regulation</u> , Vol. 8, pp. 189-196, July/August 1989
	AGG	Hock, et al., "Interleukin 7 Induces CD4 ⁺ T Cell-dependent Tumor Rejection", <u>The Journal of Experimental Medicine</u> , Vol. 174, No. 6, pp. 1291-1298, December 1, 1991
	AHH	Jaffee, "Immunotherapy of Cancer", <u>Annals of The New York Academy of Sciences</u> , Vol. 886, pp. 67-72
RCS	AH	Kim, et al., "Macrophage Colony-Stimulating Factor Can Modulate Immune Responses and Attract Dendritic Cells <i>in Vivo</i> ", <u>Human Gene Therapy</u> , Vol. 11, No. 2, pp. 305-321, January 20, 2000

Examiner Signature

RCS

Date Considered

8/8/03

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JAN 13 2003
PATENT
TRADEMARK OFFICE

RECEIVED
JAN 15 2003
TECH CENTER 1600/2906

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06666-149001	Application No. 09/997,525
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Erlinda M. Gordon et al.	
		Filing Date November 29, 2001	Group Art Unit 1646/632

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
RMS	AJJ	Knobloch, et al., "T cell receptor diversity in severe combined immunodeficiency following HLA-haploidentical bone marrow transplantation", <u>Bone Marrow Transplantation</u> , Vol. 8, No. 5, pp. 383-387, November, 1991
	AKK	Kurane, et al., "Cytokines as an Adjuvant to Tumor Vaccines: Efficacy of Local Methods of Delivery", <u>Annals of Surgical Oncology</u> , Vol. 4, No. 7, pp. 579-585, 1997
	ALL	Liu, et al., "Incorporation of Tumor Vasculature Targeting Motifs into Moloney Murine Leukemia Virus Env Escort Proteins Enhances Retrovirus Binding and Transduction of Human Endothelial Cells", <u>Journal of Virology</u> , Vol. 74, No. 11, pp. 5320-5328, 2000
	AMM	Mackensen, et al., "Immunostimulatory Cytokines in Somatic Cells and Gene Therapy of Cancer", <u>Cytokine and Growth Factor Reviews</u> , Vol. 8, No. 2, pp. 119-128, June, 1997
	ANN	Main, et al., "Human Neuroblastoma Cell Lines are Susceptible to Lysis by Natural Killer Cells But Not by Cytotoxic T Lymphocytes", <u>The Journal of Immunology</u> , Vol. 135, No. 1, pp. 242-246, July, 1985
	AOO	Mellstedt, et al., "Augmentation of the Immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors", <u>Current Opinion in Hematology</u> , Vol. 6, pp. 169-175, 1999
	APP	Mendiratta, et al., "Combination of Interleukin 12 and interferon α Gene therapy Induces a Synergistic Antitumor Response against Colon and Renal Cell Carcinoma", <u>Human Gene Therapy</u> , Vol. 11, No. 13, pp. 1851-1862, September 1, 2000
	AQQ	Miller, et al., "Intratumoral Administration of Adenoviral Interleukin 7 Gene-Modified Dendritic Cells Augments Specific Antitumor Immunity and Achieves Tumor Eradication", <u>Human Gene Therapy</u> , Vol. 11, No. 1, pp. 53-65, January 1, 2000
	ARR	Morgan, et al., "Analysis of the Functional and Host Range-Determining Regions of the Murine Ecotropic and Amphotropic Retrovirus Envelope Proteins", <u>Journal of Virology</u> , Vol. 67, No. 8, pp. 4712-4721, August, 1993
	ASS	Nabel, et al., "Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans", <u>Proceedings of the National Academy of Sciences</u> , Vol. 90, No. 23, pp. 11307-11311, December 1, 1993
	ATT	Nagai, et al., "Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice", <u>Cancer Immunology Immunotherapy</u> , Vol. 47, pp. 72-80, 1998
	ALU	Skotzko, et al., "Retroviral Vector-mediated Gene Transfer of Antisense Cyclin G1 (CYCG1) Inhibits Proliferation of Human Osteogenic Sarcoma Cells", <u>Cancer Research</u> , Vol. 55, No. 23, pp 5493-5498, December 1, 1995
	AVV	Soneoka, et al., "A transient three-plasmid expression system for the production of high titer retroviral vectors", <u>Nucleic Acids Research</u> , Vol. 23, No. 4, pp. 628-633, February 25, 1995
	AWW	Suh, et al., "Treatment of Liver Metastases from Colon Carcinoma with Autologous Tumor Vaccine Expressing Granulocyte-Macrophage Colony-stimulating Factor", <u>Journal of Surgical Oncology</u> , Vol. 72, No. 4, pp. 218-224, December, 1999
AXX	Tepper, et al., "Experimental and Clinical Studies of Cytokine Gene-Modified Tumor Cells", <u>Human Gene Therapy</u> , Vol. 5, No. 2, pp. 153-164, February, 1994	
RMS	AYY	Ucar, et al., "Sustained cytokine production and immunophenotypic changes in human neuroblastoma cell lines transduced with a human gamma interferon vector", <u>Cancer Gene Therapy</u> , Vol. 2, No. 3, pp. 171-181, 1995


Examiner Signature

RMS

Date Considered

8/8/03

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06666-149001	Application No. 09/997,525
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Erlinda M. Gordon et al.	
		Filing Date November 29, 2001	Group Art Unit 1646 1632

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
RMS	AZZ	Warren, et al., "Uses of granulocyte-macrophage colony-stimulating factor in vaccine development", <u>Current Opinion in Hematology</u> , Vol. 7, pp. 168-173, 2000
RMS	AAAA	Watanabe, et al., "Exogenous expression of mouse interferon γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity", <u>Proceedings of the National Academy of Sciences</u> , Vol. 86, No. 23, pp. 9456-9459, December, 1989

Examiner Signature RMS	Date Considered 8/8/03
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	